Literature DB >> 11176474

Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?

A Brauers1, R Buettner, G Jakse.   

Abstract

PURPOSE: We evaluated the prognostic significance of a second transurethral resection in patients with moderately and poorly differentiated T1 bladder cancer.
MATERIALS AND METHODS: A total of 47 patients with primary T1 bladder cancer were evaluated. A second transurethral resection was performed in 42 patients in case of moderately or poorly differentiated T1 bladder tumor or concomitant carcinoma in situ in the first resection. Five patients underwent immediate cystectomy due to large, multifocal and moderately or poorly differentiated pT1 disease.
RESULTS: Of the 42 patients who underwent repeat resection 15 (36%) had no tumors. Up staging and change of treatment strategy due to the result of the second resection occurred in 10 (24%) cases. Mean followup was 60 months. An R0 second resection correlated with a 33% recurrence rate at followup compared with 57%, 75% and 87.5% in patients with pTa, Tis and T1 residual tumor, respectively, in the second resection. The rate of organ preservation was also related to the result of the second resection with 100% organ preservation in patients with no tumor in the second procedure. After immediate radical cystectomy 3 of 5 patients died during followup due to disease progression. Of this group 2 patients survived without clinical or radiological signs of disease progression.
CONCLUSIONS: To our knowledge residual tumor after the first transurethral resection is a fact in bladder cancer treatment. The second transurethral resection offers the possibility to preserve the bladder. Furthermore, residual disease can be detected and removed in due time. In case of up staging to muscle infiltrating tumor, cystectomy is the next therapeutic step.

Entities:  

Mesh:

Year:  2001        PMID: 11176474

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  28 in total

1.  The value of the preoperative FISH test in unscreened bladder cancer patients with TUR indications.

Authors:  S V Petrov; K A Malkhasyan; M Yu Ulyanin; E F Abdrakhmanov; R Sh Khasanov
Journal:  Pathol Oncol Res       Date:  2012-06-23       Impact factor: 3.201

2.  The optimal management of T1 high-grade bladder cancer.

Authors:  Kenneth G Nepple; Michael A O'Donnell
Journal:  Can Urol Assoc J       Date:  2009-12       Impact factor: 1.862

Review 3.  Restaging transurethral resection of bladder tumor for high-risk stage Ta and T1 bladder cancer.

Authors:  Miguel Ramírez-Backhaus; José Domínguez-Escrig; Argimiro Collado; José Rubio-Briones; Eduardo Solsona
Journal:  Curr Urol Rep       Date:  2012-04       Impact factor: 3.092

Review 4.  Immune therapies in non-muscle invasive bladder cancer.

Authors:  Philip L Ho; Stephen B Williams; Ashish M Kamat
Journal:  Curr Treat Options Oncol       Date:  2015-02

5.  Applicability of the EORTC risk tables to predict outcomes in non-muscle-invasive bladder cancer in Turkish patients.

Authors:  Muhammet Fatih Kılınç; Göksel Bayar; Ayhan Dalkılıç; Nurettin Cem Sönmez; Serdar Arısan; Soner Güney
Journal:  Turk J Urol       Date:  2017-01-06

6.  Application of new technology in bladder cancer diagnosis and treatment.

Authors:  Alvin C Goh; Seth P Lerner
Journal:  World J Urol       Date:  2009-02-22       Impact factor: 4.226

7.  [Prevalence of lymph node metastases in non-muscle-invasive bladder cancer. Delay of radical cystectomy and upstaging in the cystectomy specimen as risk factors].

Authors:  C Wiesner; C Thomas; A Salzer; R Gillitzer; C Hampel; J W Thüroff
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

8.  [Predictors for presence of residual tumor in follow-up transurethral resection of bladder tumors: single center results].

Authors:  J Hartinger; R Häußermann; P Olbert; R Hofmann; A Hegele
Journal:  Urologe A       Date:  2013-04       Impact factor: 0.639

9.  Intravesical bacillus Calmette-Guerin therapy after second transurethral resection for primary T1 bladder cancer.

Authors:  Masato Baba; Susumu Kageyama; Tetsuya Yoshida; Ryo Fujiwara; Chul Jang Kim; Keita Takimoto; Masayuki Nagasawa; Hiroki Soga; Yukihiro Nagatani; Zenkai Nishikawa; Akihiro Kawauchi
Journal:  Int J Clin Oncol       Date:  2018-05-14       Impact factor: 3.402

10.  Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer.

Authors:  Guido Dalbagni; Kinjal Vora; Matthew Kaag; Angel Cronin; Bernard Bochner; S Machele Donat; Harry W Herr
Journal:  Eur Urol       Date:  2009-07-17       Impact factor: 20.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.